These data indicate that inhibition of the VEGFR-PI3K/AKT-CRY1 axis may be sufficient to suppress HR activation by the increase in CRY1. Several clinical trials reported that the combination of PARPi and PI3K/AKT inhibitors showed enhanced efficacy regardless of cancer type and HR status (36–38). This evidence concerns the gene AKT1 and cancer.